Kathy (Kathleen) Ogilvie

Kathy Ogilvie (Kathleen Ogilvie) has extensive experience in the field of translational pharmacology and research operations. Kathy (Kathleen) has held various senior-level positions in reputable companies and has a proven track record of leading successful research projects.

From 2020 to present, Kathy worked as the VP of Translational Pharmacology and Research Operations at Ventyx Biosciences. Prior to that, they served as the Senior Director of Translational Pharmacology at Kalika Biosciences, LLC family companies from 2018 to 2020.

Before joining Kalika Biosciences, Kathy worked as a Consultant in San Diego, CA from 2010 to 2019. Their role involved providing in vivo biology, pharmacology, and drug discovery consulting. Kathy (Kathleen) also reviewed and critiqued non-clinical regulatory submissions and evaluated literature and proprietary data for discovery and development purposes.

From 2013 to 2018, Kathy was the Director of Physiology at aTyr Pharma. Kathy (Kathleen) was responsible for conducting translational research to understand the immune modulatory effects of proprietary Physiocrines and played a key role in drafting non-clinical pharmacology, pharmacokinetics, and toxicology sections of regulatory submissions. Kathy also managed a team of biologists and oversaw the characterization of proprietary proteins and the study of non-catalytic functions of tRNA synthetases.

From 2011 to 2013, Kathy worked as an Associate Director at CovX, Pfizer Biotherapeutics and Bioinnovation Center. Their responsibilities included overseeing the metabolic disease drug discovery portfolio and supervising in vivo pharmacology and vivarium operations. Kathy (Kathleen) also led validation stage projects and evaluated collaboration opportunities.

Prior to CovX, Kathy served as the Director of Pharmacology at Exelixis from 2007 to 2010. In this role, they were responsible for in vivo pharmacology and pharmacokinetic work supporting the metabolic disease and inflammation portfolio.

From 2002 to 2007, Kathy worked at Pfizer Pharmaceuticals in various roles. Kathy (Kathleen) was an Associate Director of Diabetes Biology (Pharmacology), where they oversaw 16 biologists supporting drug discovery projects and exploratory work. Kathy also led a multidisciplinary team and represented Discovery as the clinical candidate progressed through Phase I. Kathy (Kathleen) played a key role in advancing the Peroxisome Proliferator-Activated Receptor (PPAR) project.

Kathy's career began at Ligand Pharmaceuticals in 1997, where they held research scientist positions. Kathy (Kathleen) led the metabolic disease in vivo team and performed experiments using novel nuclear receptor ligands in animal models. Kathy also co-led a collaborative project team with Eli Lilly that progressed to phase 1.

Overall, Kathy Ogilvie has a strong background in translational pharmacology, drug discovery, and research operations. Kathy (Kathleen) has demonstrated expertise in managing teams, conducting research, and contributing to regulatory submissions. Their extensive experience in the field makes their a valuable asset to any organization.

Kathy (Kathleen) Ogilvie has an education history in biological sciences. Kathy (Kathleen) earned a Bachelor of Science degree in Biology from Indiana University of Pennsylvania. Following that, they pursued a Ph.D. in Biological Sciences at the University of Delaware. Lastly, they engaged in postdoctoral research as a Research Associate at the Salk Institute for Biological Studies.